Clinical Trials Browser

Pathologic Complete Response, Bone Neoplasms, Chondrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Patient Compliance, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT07397442 2026-02-11

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

19 enrolled

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT07353840 2026-01-20

T-START-CR

Recruiting

160 enrolled

Lymphoid

Pathologic Complete Response, Lymphoma, T-Cell, Peripheral

NCT07328841 2026-01-09

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

Phase 3 Recruiting

456 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07328854 2026-01-09

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

Phase 3 Recruiting

346 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Pathologic Complete Response

Clinical Trials

MEND-IT II

I-SPY

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

REGOSTA

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

T-START-CR

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma